Phase II study: a study to explore the safety and preliminary efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab Phase III study: a confirmatory study to evaluate the safety and efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab as first-line therapy for PD-L1-positive (CPS ≥ 1) persistent, recurrent or metastatic cervical cancer
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-03.
Status change: Not Yet Recruiting → Recruiting2025-02-05